Piramal Pharma share price today

Piramal Pharma Ltd's share price was ₹237.76 at the close on 4 November 2026. It has been rising for 13 weeks. That is 25.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹138 and ₹239, and at that close it sat 99% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Piramal Pharma Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 17 weeks in a row.

Over the last 4 years the share price moved +42% while the NIFTY 500 moved +44%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

6 points on a year earlier and closed the week at a 52-week high.

1. Indian funds and insurers (DIIs) cut their stake for 3 quarters in a row

   From 15.7% to 14.4% of the company by the September 2026 quarter.

2. Operating margin up 5.6 points on a year earlier

   13.3% in the September 2026 quarter, from 7.8%.

   Why: Margins rose because India and North America did well while costs were held.

   Next results: check whether order strength turns into sales in the stronger second half.

   From the earnings call on 28 Oct 2026.

3. Closed the week at a 52-week high

   ₹238.91 on 30 Oct 2026, the highest weekly close in a year.

For July to September 2026 (the quarter ended 30 September 2026), Piramal Pharma reported revenue of ₹2,617 crore, up 28.1% from ₹2,044 crore a year earlier, and a profit of ₹5.03 crore, against a loss of ₹99.2 crore a year earlier.

Piramal Pharma results: July to September 2026 against a year earlier

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Piramal Pharma's management discussed these results on a call held on 28 October 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.

Piramal Pharma closed at ₹237.76 on 4 November 2026, up 19.4% from ₹199.15 a year earlier (7 November 2025) and up 127.2% over three years. Its highest weekly close since October 2022 was ₹281.95 on 1 November 2024.

Piramal Pharma share price: then and now

Weekly closing prices. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

218 weekly closes from 21 October 2022 to 4 November 2026.

4 Nov 2026: Piramal Pharma closed at ₹237.76, down 0.5% on the week and up 20.1% on the month. 28 Oct 2026: Piramal Pharma held its results call for July to September 2026. Management guided: FY27 revenue growth approximately 19% to 20%.

Earlier

• Results for July to September 2026: Revenue up 28.1% on a year earlier.

Piramal Pharma paid no dividend in the 12 months to 5 November 2026. The last was a dividend of ₹0.14 a share, ex-date 16 July 2025.

Piramal Pharma dividends since 1 April 2021

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here.

Not in its latest year. Piramal Pharma Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 3 of its last 6 reported years, so there is a history but no current dividend.

From the NSE corporate-actions record, read 5 November 2026.

On the call for July to September 2026, held on 28 October 2026, Piramal Pharma's management guided: FY27 revenue growth approximately 19% to 20%.

“We now expect annual revenue growth of approximately 19% to 20%, with meaningfully higher growth in profitability.”Nandini Piramal, on the call for July to September 2026

What management guided

• FY27 profitability growth meaningfully higher than revenue.
• H2 stronger than H1 with momentum continuing on order visibility.
• Full-year gross margin 64% to 65% average.
• Innovation plus on-patent to exceed 50% of CDMO in next couple years.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for July to September 2026, 28 October 2026.

When Piramal Pharma reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Kenalog supply improving as new-CMO transfer moves through validation and submission - check availability update.

Piramal Pharma is on 4 of our India lists: Momentum stocks, 52 week high & low, Small & mid cap stocks and Pharma stocks.

Piramal Pharma Ltd earned ₹5.0 Cr of net profit in the Sep 2026 quarter. The full FY26 year was a loss of ₹326 Cr. That is 0.2% of the quarter's revenue. The same quarter a year earlier lost ₹99.2 Cr. 6 of the last 12 reported quarters were loss-making.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY26 profit was −₹326 Cr (−458.2% on the year before).

Piramal Pharma Ltd reported ₹2,617 Cr of revenue in the Sep 2026 quarter, +28.1% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 5 years it has grown 7.0% a year on average. The last full year, FY26, came in at ₹8,869 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹9,779 Cr.

FY26 revenue was ₹8,869 Cr, −3.1% on the year before.

Recent pace: the last four quarters grew +10.6% on average, against 7.0% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +9.4%, against +6.0% a year over the last 8 quarters (accelerating).

Piramal Pharma Ltd's operating margin was 13.3% in the Sep 2026 quarter, 5.6 percentage points higher than the same quarter a year ago. Across 6 years it has been between 9.0% and 23.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +5.6 percentage points on the year while gross margin changed −0.3 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales.

Over the last 3 years, 549% of Piramal Pharma Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 it brought in ₹1,653 Cr of operating cash against −₹326 Cr of profit. After ₹1,505 Cr of spending on assets, ₹148 Cr was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why 549% of profit came in as cash: the cash cycle stayed about the same between FY21 and FY26, so the cash follows profit, not the cycle.

What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets.

Piramal Pharma Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 155 days in FY26, up from 147 days in FY21. It spent ₹3,284 Cr on assets over the last 3 years. Customers take 89 days to pay, and stock sits for 345 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹8,869 Cr, each day of that cycle ties up about ₹24.3 Cr, so roughly ₹3,766 Cr is tied up in the business at any time.

FY26: customers took 89 days to pay and stock sat for 345 days, about 11.3 months of sales sitting as stock, for a full cycle of 155 days, longer than FY21's 147.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 345 days. Customers pay about 89 days after that. Suppliers are paid at 279 days. Together that makes the 155-day cycle.

Spending on assets: ₹3,284 Cr over the last 3 years, against ₹2,388 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹1,100 Cr (FY26): assets paid for that are not earning yet.

In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean.

Piramal Pharma Ltd's P/E is 307.4×, in the middle of its own history: higher than 46% of past readings. Its usual P/E (the middle reading) is 316.0×, over 3 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

Why the multiple is where it is: over the past year earnings per share moved −455.1% while the price moved +19.4%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 3 years the price moved +31.5% a year; about −39.3% a year came from earnings growth and about +70.8 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple.

Piramal Pharma Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Why it matters: with too little history, we say so rather than guess a direction.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

There are fewer than eight usable quarters, so this page does not guess a direction from so little history.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the share price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Piramal Pharma Ltd earned a ROCE of 3% in FY26. That is up from a low of 2% in FY23. Its return on capital used (ROIC) is 34.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses.

Return on capital employed (ROCE) is the profit the whole business earns on all the money in it, from shareholders and lenders together. It is the best single test of whether growth adds value or just size.

It comes from a −3.7% net margin and 0.50× asset turnover (sales divided by assets).

Why the return is what it is (FY26): a −3.7% net margin × 0.50× asset turnover × 2.16× leverage (assets divided by equity) ≈ −4.0% on equity. The margin does its share; borrowing is a big part of it.

The key test, return on capital used minus the cost of capital: −22.2% − 12.0% = −34.2 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve.

The −22.2% ROIC above is the latest reading, as reported. The yearly chart below shows FY26 at 0.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

Piramal Pharma Ltd has total debt of ₹5,873 Cr against shareholder equity of ₹8,165 Cr as of Sep 2026, so its debt is 0.72× its equity. Year by year, that ratio went from 0.62 in FY22 to 0.70 in FY26. Keep that borrowing in mind when reading the returns on this page.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

Foreign institutions cut their stake in Piramal Pharma Ltd by 18.1 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 13.7% of the company. Domestic institutions moved +0.6 points over the same period, to 14.4%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings.

Who owns the company each quarter: promoters (the founders or controlling owners), foreign institutions, domestic institutions such as mutual funds, and the public. When people close to the business steadily raise their stake, that is worth noticing; a quiet list is also an answer.

Over the last two years: Foreign institutions: −18.1 points over 8 quarters, to 13.7%; Domestic institutions: +0.6 points over 8 quarters, to 14.4%; Promoters: −0.1 points over 8 quarters, to 34.8%.

Why the owners changed: foreign institutions drove it (−18.1 points), with the other side taken by domestic institutions (+0.6 points). They reduced their stake.

For Piramal Pharma Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

44.6 out of 100, rank 16 of 24 in Pharma - API & CRAMS, with 71% of the evidence available.

Piramal Pharma Ltd scores 44.6 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 16. Relative strength against the index is 40.9%, and revenue and profit growth are weak.

The four parts add up to the total exactly: 17 + 2 + 10 + 15.6 = 44.6. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Piramal Pharma ranks 16 of 24 Pharma - API & CRAMS companies on the 4-Factor Sector Score, with 44.6 out of 100.

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Pharma - API & CRAMS, all 24 compared on one page.

Piramal Pharma is the 7th largest of 24 Pharma - API & CRAMS companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Anthem Biosciences, Sai Life Sciences and Acutaas Chemicals. Just below it: Neuland Laboratories, Granules India and Shilpa Medicare.

Pharma - API & CRAMS companies close in size

4. Anthem Biosciences Ltd ₹46,689 crore
5. Sai Life Sciences Ltd ₹33,093 crore
6. Acutaas Chemicals Ltd ₹32,778 crore
7. Piramal Pharma Ltd ₹31,807 crore
8. Neuland Laboratories Ltd ₹25,275 crore
9. Granules India Ltd ₹22,907 crore
10. Shilpa Medicare Ltd ₹18,690 crore

All 24 Pharma - API & CRAMS companies, largest first

Companies close in size in other industries

268. Endurance Technologies Ltd ₹31,978 crore · Auto Ancillaries - Diversified
269. P I Industries Ltd ₹31,861 crore · Pesticides/Agrochemicals
270. Piramal Pharma Ltd ₹31,807 crore
271. Dhoot Transmission Ltd ₹31,611 crore
272. NLC India Ltd ₹31,608 crore · Power - Generation/Distribution

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.